Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his price target on the pharmaceutical giant. Even though that reduction was substantial, the pundit still sees value in the stock. Read on for more about this intriguing dynamic.

Down but far from out

On Thursday morning, BMO Capital's Evan David Seigerman made his move on Eli Lilly. He knocked $110 per share off his price target for a new fair-value assessment of $900 per share, while maintaining an outperform (which means buy) recommendation on the shares.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

While Seigerman waxed bullish about the company's hottest product at the moment (obesity drug Zepbound), he expressed concerns about the broader macroeconomic environment. According to reports, he feels economic pressures are affecting the entire healthcare sector, and as a standard bearer for American pharmaceuticals, Eli Lilly is vulnerable to them.

That being said, the analyst was clearly impressed by the company's momentum with Zepbound. His research indicates that it's notably pulling ahead of Novo Nordisk, which produces Wegovy, the only other GLP-1 treatment approved by the U.S. Food and Drug Administration specifically for weight loss.

This sector is an effective hedge

The currently volatile global macroeconomy can't be ignored and will probably remain shaky as long as the current trade war rages to any degree. However, pharmaceutical companies are better insulated against this than most industries, as a great many drugs aren't luxuries or options (including, for many determined patients, obesity drugs). I think Eli Lilly is still a fine stock to own.

Should you invest $1,000 in Eli Lilly right now?

Before you buy stock in Eli Lilly, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $532,771!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $593,970!*

Now, it’s worth noting Stock Advisor’s total average return is 781% — a market-crushing outperformance compared to 149% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of April 21, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.